4IPH fundamentals
An in-depth look to INNATE PHARMA operating, investing, and financing activities
4IPH free cash flow for H2 24 is -10.04 M EUR. For 2024, 4IPH free cash flow was -7.29 M EUR and operating cash flow was -6.9 M EUR.
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: EUR
TTM